https://www.thebodypro.com/author/barbara-jungwirth

Latest by Barbara Jungwirth

Medicines Patent Pool Model May Expand Beyond HIV Medications Img

Medicines Patent Pool Model May Expand Beyond HIV Medications

The Medicines Patent Pool, which negotiates licenses with the manufacturers of new drugs that allow other companies to produce generic versions for distribution in low- and middle-income countries, is looking to expand beyond HIV drugs to medications...

This Week in HIV Research: Gendered Nuances in Care and Complications

Alcohol use worsens HIV care outcomes; sex-based differences in cognitive performance seen; higher cardiovascular risk among trans women; glycemic status related to cognitive function.

Public Health Approach = Do the Best for the Most People Using Resources Efficiently Img

Public Health Approach = Do the Best for the Most People Using Resources Efficiently

While almost 60% of people living with HIV globally are on treatment, the numbers for new seroconversions averted and HIV-related deaths are no longer improving.

European continent marked with flags
News

HIV Stigma Still Common in Europe, Survey Finds

In a recent survey of people not living with HIV, many still believed that people living with HIV should not be allowed to work in hospitals, restaurants, or universities, among other occupations, and 68% said they would be uncomfortable dating someo...

More People With HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows Img

More People With HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows

After 96 weeks, more people achieved viral suppression on a doravirine-based antiretroviral drug regimen compared with a darunavir (Prezista)-based one, according to data presented at the recent 22nd International AIDS Conference.

This Week in HIV Research: Treatment Does a Body Good

Early treatment reduces health risks; on-demand PrEP more popular than daily pill among French MSM; long-acting injectable PrEP preferred over daily pill in Swaziland; HIV-positive MSM aren’t testing for syphilis enough.

This Week in HIV Research: Another Notch in the 'Treatment as Prevention' Belt

“Opposites Attract” study piles on more data backing U=U; mixed results on enhanced HIV interventions among African sex workers; the tipping point for re-engagement in HIV care; thyroid function in the modern treatment era.

Dolutegravir-Based Two-Drug Regimen Just as Good for HIV Treatment as Three-Drug Therapy, Study Says Img

Dolutegravir-Based Two-Drug Regimen Just as Good for HIV Treatment as Three-Drug Therapy, Study Says

A dolutegravir-based two-drug regimen was non-inferior to the standard three-drug therapy among treatment-naive participants, according to results from the two GEMINI trials presented at the International AIDS Conference in Amsterdam, the Netherlands...

Latinx

This Week in HIV Research: Mitigating an ICE-y Reception

HIV ramifications of the Trump administration’s anti-immigration efforts; HIV in plasma vs. rectal tissue; how HCV treatment affects HIV/HCV coinfection; HPV vaccination efficacy among women with HIV.

This Week in HIV Research: A Yawning Racial Gap in U.S. Testing

HIV testing disparities among black MSM in the Southern U.S.; reasons for non-adherence in a vaginal HIV prevention ring trial; the importance of PrEP despite successful HIV treatment; inaccurate antiretroviral usage rates in Africa.